Liu Hai-Ning, Wu Hao, Chen Yu-Zhuo, Chen Yan-Jie, Shen Xi-Zhong, Liu Tao-Tao
Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai, China.
Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, China.
Dig Liver Dis. 2017 Apr;49(4):331-337. doi: 10.1016/j.dld.2017.01.142. Epub 2017 Jan 21.
Many studies have reported significant changes in intestinal microbiota in irritable bowel syndrome (IBS) patients based on quantitative real-time PCR analysis.
We aimed to review the alterations in intestinal microbiota.
An online search up to June 9, 2016, was conducted. This systematic review and meta-analysis included differential expression of intestinal microbiota in patients with IBS versus healthy controls (HCs) and subgroup analysis. We assessed the quality of the included studies using an original assessment tool.
A total of 13 articles involving 360 IBS patients and 268 healthy controls were included. The quality assessment scores for these articles ranged from 5 to 8. Significant differences in expression in IBS patients were observed for Lactobacillus (SMD=-0.85, P<0.001, I=28%), Bifidobacterium (SMD=-1.17, P<0.001, I=79.3%), and Faecalibacterium prausnitzii (SMD=-1.05, P<0.001, I=0.0%) but not Bacteroides-Prevotella group, Escherichia coli or other genera or species. Subgroup analysis showed that diarrhea-predominant IBS patients had significantly different expression of Lactobacillus (SMD=-1.81, P<0.001) and Bifidobacterium (SMD=-1.45, P<0.001).
Down-regulation of bacterial colonization including Lactobacillus, Bifidobacterium and F. prausnitzii was observed in IBS patients, particularly in diarrhea-predominant IBS (IBS-D). Microbiota changes participate in the pathogenesis of IBS and may underlie the efficacy of probiotic supplements.
许多研究报告称,基于定量实时聚合酶链反应分析,肠易激综合征(IBS)患者的肠道微生物群有显著变化。
我们旨在综述肠道微生物群的改变。
进行了截至2016年6月9日的在线搜索。这项系统评价和荟萃分析包括IBS患者与健康对照(HCs)肠道微生物群的差异表达及亚组分析。我们使用一种原创评估工具评估纳入研究的质量。
共纳入13篇文章,涉及360例IBS患者和268例健康对照。这些文章的质量评估分数在5至8分之间。IBS患者中,乳酸杆菌(标准化均数差=-0.85,P<0.001,I=28%)、双歧杆菌(标准化均数差=-1.17,P<0.001,I=79.3%)和普拉梭菌(标准化均数差=-1.05,P<0.001,I=0.0%)的表达存在显著差异,但拟杆菌-普雷沃菌属、大肠杆菌或其他属或种无显著差异。亚组分析显示,腹泻型IBS患者的乳酸杆菌(标准化均数差=-1.81,P<0.001)和双歧杆菌(标准化均数差=-1.45,P<0.001)表达有显著差异。
IBS患者中观察到包括乳酸杆菌、双歧杆菌和普拉梭菌在内的细菌定植下调,尤其是在腹泻型IBS(IBS-D)中。微生物群变化参与IBS的发病机制,可能是益生菌补充剂疗效的基础。